Calcineurin Inhibition in Deceased Organ Donors: A Systematic Review and Meta-analysis of Preclinical Studies.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
13
03
2023
revised:
01
05
2023
accepted:
03
05
2023
medline:
31
8
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
epublish
Résumé
Preconditioning deceased organ donors with calcineurin inhibitors (CNIs) may reduce ischemia-reperfusion injury to improve transplant outcomes. We searched MEDLINE, EMBASE, Cochrane Library, and conference proceedings for animal models of organ donation and transplantation, comparing donor treatment with CNIs with either placebo or no intervention, and evaluating outcomes for organ transplantation. Reviewers independently screened and selected studies, abstracted data, and assessed the risk of bias and clinical relevance of included studies. Where possible, we pooled results using meta-analysis; otherwise, we summarized findings descriptively. Eighteen studies used various animals and a range of CNI agents and doses and evaluated their effects on a variety of transplant outcomes. The risk of bias and clinical applicability were poorly reported. Pooled analyses suggested benefit of CNI treatment on early graft function in renal transplants (3 studies; serum creatinine: ratio of means [RoM] 0.54; 95% confidence interval [CI], 0.34-0.86) but not for liver transplants (2 studies; serum alanine transaminase: RoM 0.61; 95% CI, 0.30-1.26; and serum aspartate aminotransferase: RoM 0.58; 95% CI, 0.26-1.31). We found no reduction in graft loss at 7 d (2 studies; risk ratio 0.54; 95% CI, 0.08-3.42). CNI treatment was associated with reduced transplant recipient levels of interleukin-6 (4 studies; RoM 0.36; 95% CI, 0.19-0.70), tumor necrosis factor-alpha (5 studies; RoM 0.36; 95% CI, 0.12-1.03), and cellular apoptosis (4 studies; RoM 0.30; 95% CI, 0.19-0.47). Although this compendium of animal experiments suggests that donor preconditioning with CNIs may improve early kidney graft function, the limited ability to reproduce a true clinical environment in animal experiments and to assess for risk of bias in these experiments is a serious weakness that precludes current clinical application.
Sections du résumé
Background
UNASSIGNED
Preconditioning deceased organ donors with calcineurin inhibitors (CNIs) may reduce ischemia-reperfusion injury to improve transplant outcomes.
Methods
UNASSIGNED
We searched MEDLINE, EMBASE, Cochrane Library, and conference proceedings for animal models of organ donation and transplantation, comparing donor treatment with CNIs with either placebo or no intervention, and evaluating outcomes for organ transplantation. Reviewers independently screened and selected studies, abstracted data, and assessed the risk of bias and clinical relevance of included studies. Where possible, we pooled results using meta-analysis; otherwise, we summarized findings descriptively.
Results
UNASSIGNED
Eighteen studies used various animals and a range of CNI agents and doses and evaluated their effects on a variety of transplant outcomes. The risk of bias and clinical applicability were poorly reported. Pooled analyses suggested benefit of CNI treatment on early graft function in renal transplants (3 studies; serum creatinine: ratio of means [RoM] 0.54; 95% confidence interval [CI], 0.34-0.86) but not for liver transplants (2 studies; serum alanine transaminase: RoM 0.61; 95% CI, 0.30-1.26; and serum aspartate aminotransferase: RoM 0.58; 95% CI, 0.26-1.31). We found no reduction in graft loss at 7 d (2 studies; risk ratio 0.54; 95% CI, 0.08-3.42). CNI treatment was associated with reduced transplant recipient levels of interleukin-6 (4 studies; RoM 0.36; 95% CI, 0.19-0.70), tumor necrosis factor-alpha (5 studies; RoM 0.36; 95% CI, 0.12-1.03), and cellular apoptosis (4 studies; RoM 0.30; 95% CI, 0.19-0.47).
Conclusions
UNASSIGNED
Although this compendium of animal experiments suggests that donor preconditioning with CNIs may improve early kidney graft function, the limited ability to reproduce a true clinical environment in animal experiments and to assess for risk of bias in these experiments is a serious weakness that precludes current clinical application.
Identifiants
pubmed: 37649790
doi: 10.1097/TXD.0000000000001519
pmc: PMC10465100
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1519Informations de copyright
Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Références
Lancet Respir Med. 2018 May;6(5):357-367
pubmed: 29650408
N Engl J Med. 2009 Jan 1;360(1):7-19
pubmed: 19118301
Annu Rev Physiol. 1998;60:619-42
pubmed: 9558479
Transplant Proc. 2005 May;37(4):1931-3
pubmed: 15919508
Liver Transpl. 2003 Feb;9(2):105-16
pubmed: 12548502
Am J Transplant. 2022 Apr;22(4):1169-1181
pubmed: 34856070
Front Immunol. 2020 Jun 18;11:1222
pubmed: 32625210
BMC Med Res Methodol. 2014 Mar 26;14:43
pubmed: 24667063
Am J Nephrol. 2010;31(2):134-40
pubmed: 19923799
Int J Evid Based Healthc. 2015 Sep;13(3):196-207
pubmed: 26355603
Curr Urol Rep. 2019 Jan 26;20(1):6
pubmed: 30685826
BMC Med Res Methodol. 2008 May 21;8:32
pubmed: 18492289
Circ Res. 2016 Apr 15;118(8):1223-32
pubmed: 26888636
Nephrol Dial Transplant. 2006 Jun;21(6):1689-96
pubmed: 16490743
Cytokine. 2009 Feb;45(2):141-7
pubmed: 19138532
Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103
pubmed: 32301874
Am J Transplant. 2017 May;17(5):1346-1357
pubmed: 27873464
J Cereb Blood Flow Metab. 2005 Jun;25(6):713-21
pubmed: 15703698
Transplantation. 2003 Jun 15;75(11):1786-92
pubmed: 12811235
Clin Exp Immunol. 2012 Jan;167(1):169-77
pubmed: 22132896
Dis Model Mech. 2014 Dec;7(12):1321-33
pubmed: 25481012
J Med Invest. 2004 Feb;51(1-2):76-83
pubmed: 15000260
Am J Transplant. 2022 Feb;22(2):344-370
pubmed: 34657378
J Surg Res. 2012 Jun 15;175(2):333-42
pubmed: 21696775
Ann Intern Med. 2005 Apr 5;142(7):510-24
pubmed: 15809463
Nephrol Dial Transplant. 2014 Jun;29(6):1134-40
pubmed: 24335382
J Heart Lung Transplant. 2010 Aug;29(8):914-56
pubmed: 20643330
JAMA. 2006 Oct 11;296(14):1731-2
pubmed: 17032985
Health Technol Assess. 2003;7(25):1-94
pubmed: 14499050
Transplant Proc. 2006 Jul-Aug;38(6):1775-8
pubmed: 16908278
J Surg Res. 2005 Dec;129(2):202-20
pubmed: 15936035
Cardiovasc Res. 2002 Aug 15;55(3):534-43
pubmed: 12160950
Arch Pharm Res. 2009 Feb;32(2):215-20
pubmed: 19280151
Einstein (Sao Paulo). 2015 Jan-Mar;13(1):129-35
pubmed: 25993079
Clin Transplant. 1998 Jun;12(3):260-2
pubmed: 9642520
J Clin Invest. 2007 Sep;117(9):2583-91
pubmed: 17717604
Kidney Int. 2016 Mar;89(3):648-58
pubmed: 26880458
Am J Respir Crit Care Med. 2022 Sep 1;206(5):584-595
pubmed: 35549669
Nephrol Dial Transplant. 2011 Jun;26(6):1813-20
pubmed: 21068143
Transpl Immunol. 2011 Jan 15;24(2):107-12
pubmed: 21034830
Brain. 2007 Dec;130(Pt 12):3063-74
pubmed: 17478443
J Thorac Cardiovasc Surg. 2013 Nov;146(5):1213-9; discussion 1219
pubmed: 24029291
Trials. 2018 Apr 17;19(1):231
pubmed: 29665840
Transplant Proc. 1999 Feb-Mar;31(1-2):1290-2
pubmed: 10083576
Transplant Proc. 2018 Mar;50(2):539-542
pubmed: 29579846
Surgery. 2007 May;141(5):667-77
pubmed: 17462468
Transplantation. 2009 Feb 15;87(3):326-9
pubmed: 19202436
Transplantation. 1991 Oct;52(4):615-21
pubmed: 1926340
Crit Care Med. 2010 Dec;38(12):2401-8
pubmed: 20890192
Am J Transplant. 2018 Jan;18 Suppl 1:114-171
pubmed: 29292605
Transplant Proc. 1996 Jun;28(3):1902-3
pubmed: 8658938
Curr Opin Organ Transplant. 2014 Aug;19(4):395-400
pubmed: 24905021
Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1642-1650
pubmed: 31540931